David Herrington to Estrogens
This is a "connection" page, showing publications David Herrington has written about Estrogens.
Connection Strength
1.299
-
Lakoski SG, Liu Y, Brosnihan KB, Herrington DM. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. Atherosclerosis. 2008 Mar; 197(1):443-7.
Score: 0.269
-
Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J. 2007 Mar; 153(3):439-44.
Score: 0.261
-
Herrington DM. Role of estrogen receptor-alpha in pharmacogenetics of estrogen action. Curr Opin Lipidol. 2003 Apr; 14(2):145-50.
Score: 0.199
-
Klein KP, Herrington DM. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women. Medscape Womens Health. 2002 Sep-Oct; 7(5):2.
Score: 0.191
-
Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM. Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood. 2007 Mar 01; 109(5):1862-9.
Score: 0.064
-
Hsia J, Criqui MH, Herrington DM, Manson JE, Wu L, Heckbert SR, Allison M, McDermott MM, Robinson J, Masaki K. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. Am Heart J. 2006 Jul; 152(1):170-6.
Score: 0.062
-
Mellen PB, Cefalu WT, Herrington DM. Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2006 Jan; 26(1):189-93.
Score: 0.059
-
Herrington DM, Howard TD. From presumed benefit to potential harm--hormone therapy and heart disease. N Engl J Med. 2003 Aug 07; 349(6):519-21.
Score: 0.051
-
Herrington DM, Howard TD. ER-alpha variants and the cardiovascular effects of hormone replacement therapy. Pharmacogenomics. 2003 May; 4(3):269-77.
Score: 0.050
-
Byington RP, Furberg CD, Herrington DM, Herd JA, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Ireland CC, Applegate WB. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol. 2002 Oct 01; 22(10):1692-7.
Score: 0.048
-
Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006 May 23; 113(20):2425-34.
Score: 0.015
-
Nair GV, Chaput LA, Vittinghoff E, Herrington DM. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest. 2005 May; 127(5):1498-506.
Score: 0.014
-
Waters DD, Gordon D, Rossouw JE, Cannon RO, Collins P, Herrington DM, Hsia J, Langer R, Mosca L, Ouyang P, Sopko G, Stefanick ML. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials. Circulation. 2004 Feb 17; 109(6):e53-5.
Score: 0.013